Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.